Researchers observed durable responses in patients with renal cell carcinoma treated with the PD-L1 antibody MPDL3280A. The study, which was presented at the 2013 ASCO Annual Meeting, was one of the few immune therapy trials that allowed patients with non-clear cell histologies and some clinical activity was observed in these patients.
The use of statins was independently associated with improvements in overall survival and disease-specific survival among a group of patients who had undergone partial or radical nephrectomy for renal cell carcinoma.
A study found that robotic partial nephrectomy to remove kidney cancer tumors resulted in better outcomes, but also had significantly higher hospital charges. The data were presented at the annual meeting of the American Urological Association.
The FDA’s Oncologic Drugs Advisory Committee has voted 13 to 1 against AVEO's drug tivozanib for the treatment of patients with metastatic renal cell carcinoma.
A new immunoassay that tests for the presence of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) may be an effective method for the early detection of malignant kidney cancer.
Even those renal cell carcinomas (RCCs) that are smaller than 4 cm may put patients at risk for aggressive cancer, according to a new study presented at the 28th Annual European Association of Urology Congress in Milan, Italy.
Acetaminophen and nonaspirin nonsteroidal anti-inflammatory drugs were associated with a 28% increased risk of developing kidney cancer, according to the results of a recently published meta-analysis.
High levels of physical activity were linked with a 22% decreased risk for renal cancer, according to a meta-analysis that looked at results from 19 studies that quantified the relationship with physical activity and renal cancer.
One way of framing the ethical question in this case might be: “What are my ethical obligations to provide an anticancer therapy when I think it is unlikely to benefit the patient?” The broader clinical questions involved in this case are fundamentally the same in most patients.
A trial comparing axitinib to sorafenib as first-line therapy for metastatic renal cell carcinoma showed a statistically significant improvement in progression-free survival for the drug; however, the difference failed to meet the phase III trial’s prespecified significance level of 0.025.
Results from a retrospective analysis indicate that the use of the antiangiogenic, VEGF inhibitor sorafenib for the treatment of advanced renal cell carcinoma was well tolerated in patients aged 65 years or older.
New data suggest that surveillance of patients with small kidney tumors may be a safe alternative to surgery, especially in older patients or those with comorbid conditions.
In a new study, researchers show that sunitinib, an FDA-approved TKI for advanced renal cell carcinoma, does not result in accelerated growth of kidney tumors after discontinuing treatment.
The mTOR inhibitor everolimus (Afinitor) has been found to significantly reduce the size of angiomyolipomas, the slow-growing benign tumors commonly associated with tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis, according to the results of the phase III EXIST-2 study.
A new technique of robotic partial nephrectomy has the potential for better preservation of kidney function and better cancer control during partial nephrectomy by allowing surgeons more time to perform the procedure compared with traditional open surgery, according to the results of a recently published case series.
Screening patients with renal masses with iodine-124-girentuximab had both a high specificity and sensitivity for identifying clear cell renal cell carcinoma, according to the results of a newly published open-label multicenter study.
In mid-October, Pfizer announced that its phase III study being conducted examining axitinib (Inlyta) in treatment-naive patients with advanced renal cell carcinoma failed to meet its primary endpoint of improving progression-free survival compared with sorafenib.
Black patients diagnosed with renal cell carcinoma had worse survival than white patients regardless of several patient and tumor characteristics including tumor stage and size, according to data from 39,350 patients in the National Cancer Institute’s SEER program.
A phase I study of the use of stereotactic radiosurgery as a therapeutic option for patients with localized, inoperable primary renal cancer showed that the treatment modality effectively stabilized or decreased disease in a large percentage of patients.
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).
The randomized COMPARZ trial of pazopanib vs sunitinib for metastatic renal cell carcinoma found a similar response to both, but pazopanib was more tolerable.
AVEO Pharmaceuticals Inc has announced that it has submitted a new drug application for tivozanib to the US Food and Drug Administration for the treatment of metastatic renal cell carcinoma.
Results from a trial of a new therapeutic vaccine for renal cell carcinoma demonstrate that those patients with a measurable immune response to the vaccine have a prolonged overall survival.
In this issue of ONCOLOGY, Dutcher, Mourad, and Ennis provide a current review of some newer strategies in the surgical and systemic treatment options for localized and advanced renal cell carcinoma (RCC).
Drs. Dutcher, Mourad, and Ennis have provided an excellent review of current and potential future treatments of renal cell carcinoma (RCC); we would like to highlight some salient points from a urologic perspective.
